Compare BURL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BURL | JAZZ |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 16.1B |
| IPO Year | 2013 | 2007 |
| Metric | BURL | JAZZ |
|---|---|---|
| Price | $242.02 | $242.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 22 |
| Target Price | ★ $358.47 | $296.77 |
| AVG Volume (30 Days) | ★ 1.2M | 745.1K |
| Earning Date | 11-24-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.92 | N/A |
| EPS | ★ 4.67 | 0.04 |
| Revenue | ★ $11,566,910,000.00 | $1,618,693,000.00 |
| Revenue This Year | $10.96 | $12.57 |
| Revenue Next Year | $8.79 | $5.14 |
| P/E Ratio | ★ $53.72 | $6,059.13 |
| Revenue Growth | ★ 8.76 | N/A |
| 52 Week Low | $226.85 | $156.95 |
| 52 Week High | $378.33 | $266.38 |
| Indicator | BURL | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 61.88 |
| Support Level | $229.30 | $236.70 |
| Resistance Level | $263.03 | $250.49 |
| Average True Range (ATR) | 8.64 | 7.34 |
| MACD | 1.17 | 3.76 |
| Stochastic Oscillator | 32.02 | 84.08 |
Burlington Stores Inc is an off-price retailer offering an extensive selection of in-season, fashion-focused merchandise, including women's ready-to-wear apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts, and coats. The company sells a broad selection of desirable, first-quality, current-brand, labeled merchandise acquired directly from nationally recognized manufacturers and other suppliers. It sells products in categories such as Ladies apparel, Accessories and shoes, Home, Mens apparel, Kids apparel and baby, and Outerwear.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.